Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Gemcitabine/Cisplatin in R/M-NPC
NCT03639467Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Sep 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in nasopharyngeal carcinoma (NPC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
anlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03639467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639467.